| Literature DB >> 35225530 |
Ashi Khurana1, Ajit Kumar1, Lokesh Chauhan2.
Abstract
PURPOSE: To determine the seasonality, clinical profile, and treatment outcome of Fusarium keratitis.Entities:
Keywords: Fusarium sp; hypopyon; keratitis; sugarcane leaf injury; trauma
Mesh:
Substances:
Year: 2022 PMID: 35225530 PMCID: PMC9114586 DOI: 10.4103/ijo.IJO_999_21
Source DB: PubMed Journal: Indian J Ophthalmol ISSN: 0301-4738 Impact factor: 1.848
Demographic characteristics of patients
| Variable | Category | Frequency | Percent |
|---|---|---|---|
| Age (years) | <18 | 4 | 4.3 |
| 18-25 | 10 | 10.6 | |
| 26-35 | 11 | 11.7 | |
| 36-45 | 18 | 19.1 | |
| 46-55 | 24 | 25.5 | |
| 56-65 | 19 | 20.2 | |
| >65 | 8 | 8.5 | |
| Gender | Female | 19 | 20.2 |
| Male | 75 | 79.8 | |
| Location | Rural | 79 | 84.0 |
| Urban | 15 | 16.0 | |
| Duration between onset of symptoms and presentation (days) | <7 | 30 | 40.4 |
| 8-14 | 25 | 26.6 | |
| 15-30 | 19 | 20.2 | |
| >30 | 12 | 12.8 | |
| Season | Winter | 9 | 9.6 |
| Spring | 3 | 3.2 | |
| Summer | 32 | 34.0 | |
| Monsoon | 22 | 23.4 | |
| Autumn | 28 | 29.8 | |
| Medication before presentation | Yes | 79 | 84.0 |
| No | 15 | 16.0 |
Figure 1Distribution of inciting causes of Fusarium keratitis
Medications at the time of presentation
| Drug 1 | Drug 2 | Drug 3 | Drug 4 | No of Pts |
|---|---|---|---|---|
| Fluoroquinolones | Nil | 7 | ||
| Antihistamine | 1 | |||
| Anesthetic | 2 | |||
| Azole antifungal | Nil | 4 | ||
| Chloramphenicol | 1 | |||
| Quinolone | 1 | |||
| Aminoglycoside | 1 | |||
| Steroid | 2 | |||
| Aminoglycoside | Nil | 4 | ||
| Quinolone | 1 | |||
| Anesthetic | 2 | |||
| Natamycin | Nil | 4 | ||
| Aminoglycoside | 1 | |||
| Anesthetic | 1 | |||
| Triazole antifungal | 2 | |||
| Azole antifungal | Nil | 3 | ||
| Triazole antifungal | 2 | |||
| Aminoglycoside | Triazole antifungal | 2 | ||
| Imidazole antifungal | Anesthetic | 3 | ||
| Natamycin | Nil | 1 | ||
| Chloramphenicol | 2 | |||
| Azole Antifungal | 3 | |||
| Polymyxins | Antiviral | 1 | ||
| Quinolone | Azole antifungal | 1 | ||
| Quinolone | Nil | 1 | ||
| Steroid | 1 | |||
| Azole antifungal | 1 | |||
| Aminoglycoside | Nil | 1 | ||
| Imidazole antifungal | 1 | |||
| Triazole antifungal | 1 | |||
| Azole antifungal | Beta-lactams | 1 | ||
| Chloramphenicol | Steroid | 1 | ||
| Antiviral | Nil | 1 | ||
| Anesthetic | Nil | 1 |
Figure 2Clinical characteristics of Fusarium keratitis (a) feathery margin, (b) grey infiltrate, (c) active edges, (d) resolving infiltrate, (e) ring infiltrate, (f) dry plaque
Cross-tabulation [Presenting BCVA vs. Final BCVA]
| Presenting BCVA | BCVA at last follow-up | |||
|---|---|---|---|---|
|
| ||||
| >20/30 | 20/30-20/60 | 20/60-20/200 | <20/200 | |
| >20/30 | 8 [50%, 50%] | 4 [25%, 26.7%] | 3 [18.8%, 16.7%] | 1 [6.3%, 2.2%] |
| 20/30-20/60 | 3 [25%, 18.8%] | 4 [33.3%, 26.7%] | 2 [16.7%, 11.1%] | 3 [25%, 6.7%] |
| 20/60-20/200 | 2 [15.4%, 12.5%] | 2 15.4%, 13.3%] | 7 [53.8%, 38.9%] | 2 [15.4%, 4.4%] |
| <20/200 | 3 [5.7%, 18.8%] | 5 [9.4%, 33.3%] | 6 [11.3%, 33.3%] | 39 [73.6%, 86.7%] |
P=0.00; Fisher exact test [Frequency distribution of categories are statistically significant]
Adjuvant Therapy
| Drug 1 | Drug 2 | Drug 3 | Drug 4 | Drug 5 | Drug 6 | No of Patients |
|---|---|---|---|---|---|---|
| Natamycin | Nil | 7 | ||||
| Anticholinergic | Ibuprofen/paracetamol (T) | 9 | ||||
| Ibuprofen/paracetamol (T) | Lubricating | 2 | ||||
| Cephalosporin | Fluoroquinolones | Anticholinergic | Ibuprofen/paracetamol (T) | 1 | ||
| Azole (T) | Triazole | Anticholinergic | Lubricating | 2 | ||
| Ibuprofen/paracetamol (T) | Nil | 10 | ||||
| Lubricating | 2 | |||||
| Anticholinergic | Ibuprofen/paracetamol (T) | Nil | 35 | |||
| Lubricating | 6 | |||||
| Lubricating | 3 | |||||
| Nil | 1 | |||||
| Triazole | Anticholinergic | Ibuprofen/paracetamol (T) | Lubricating | 1 | ||
| Lubricating | 1 | |||||
| Cephalosporin | Fluoroquinolones | Anticholinergic | Ibuprofen/paracetamol (T) | 7 | ||
| Antiviral | Anticholinergic | Ibuprofen/paracetamol (T) | 1 | |||
| Anticholinergic | Ibuprofen/paracetamol (T) | 1 | ||||
| Fluoroquinolones | Anticholinergic | Ibuprofen/paracetamol (T) | Lubricating | 1 | ||
| Anticholinergic | Ibuprofen/paracetamol (T) | 1 | ||||
| Lubricating | 1 | |||||
| Triazole | Ibuprofen/paracetamol (T) | 1 | ||||
| Anticholinergic | Lubricating | 1 |
Best-corrected visual acuity at the last follow up in different groups
| Variable | Category |
| BCVA at last follow-up |
| |
|---|---|---|---|---|---|
|
| |||||
| Mean [log MAR] | Std. Deviation | ||||
| Days from onset of symptoms to presentation | ≥7 Days | 56 | 1.52 | 1.250 | 0.15 |
| <7 Days | 38 | 1.13 | 1.119 | ||
| Inciting Cause | Yes | 61 | 1.39 | 1.187 | 0.72 |
| No | 33 | 1.30 | 1.262 | ||
| Infiltrate Size | >4 mm2 | 64 | 1.75 | 1.155 | 0.00* |
| ≤4 mm2 | 30 | 0.53 | 0.860 | ||
| Hypopyon | Yes | 12 | 1.75 | 1.215 | 0.21 |
| No | 82 | 1.30 | 1.204 | ||
| Surgery | Yes | 26 | 2.27 | 1.002 | 0.00* |
| No | 68 | 1.01 | 1.099 | ||
| Re-surgery | Yes | 14 | 2.43 | 0.852 | 0.00* |
| No | 80 | 1.18 | 1.167 | ||
*Statistically significant
Distribution of characteristics among medically and surgically managed patients
| Variable | Category | Medical Management | Surgical Management | Total |
|
|---|---|---|---|---|---|
| Ulcer Location | Central | 35 | 23 | 58 | <0.001 |
| Paracentral | 34 | 2 | 36 | ||
| Infiltrate Category | <4 mm | 19 | 3 | 22 | 0.11 |
| >4 mm | 50 | 22 | 72 | ||
| Presenting VA | >20/30 | 15 | 1 | 16 | 0.003 |
| 20/30-20/60 | 11 | 1 | 12 | ||
| 20/60-20/200 | 12 | 1 | 13 | ||
| <20/200 | 31 | 22 | 53 | ||
| Hypopyon | No | 63 | 19 | 82 | 0.04 |
| Yes | 6 | 6 | 12 | ||
| Medication at Presentation | No | 12 | 3 | 15 | 0.52 |
| Yes | 57 | 22 | 79 | ||
| Duration between symptom and presentation | <7 Days | 24 | 3 | 27 | 0.03 |
| >7 Days | 45 | 22 | 67 |